Primary Sclerosing Cholangitis Clinical Trial
— PIP-COfficial title:
Investigation of the Effect of Raised Serum Bile Acids on the Epigenome of Sperm and the Association With the Metabolic Health of the Children of Men With Cholestasis: a Case-control Study.
NCT number | NCT03337074 |
Other study ID # | 182833 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | February 8, 2017 |
Est. completion date | April 30, 2020 |
For some years investigators have known that the health of fathers at the time their baby is
conceived has an influence on the health of their child in the future. Many studies looking
at this effect have investigated fathers with obesity and other metabolic disorders. These
disorders can alter the risk of obesity and diabetes in the children of these men. More
recently, studies have been undertaken to establish the mechanism by which this risk is
inherited by the children. Studies of sperm have identified that changes in the structure and
function of the sperm play a role.
Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis (PBC) are included in a
group of cholestatic liver disorders that are associated with elevated levels of bile acids
in the blood (cholestasis). A previous study has established that children born to women who
have cholestasis during pregnancy are at an increased risk of obesity later in life. Our
study will investigate whether there is a similar effect on the health of children if their
father has cholestasis.
The study has 2 arms, the Sperm Epigenome arm and the Outcomes arm.
In the Sperm Epigenome arm of the study, the structure and function of sperm from men with
PSC, PBC and other cholestatic liver disorders will be investigated and compared to the
structure and function of sperm from healthy men.
In the Outcomes arm of the study, basic health parameters of fathers who had PSC, PBC or
another cholestatic liver disease either before or after their child was conceived will be
studied. Basic health parameters will also be studied in their child when the child is
between 16 and 25 years of age.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | April 30, 2020 |
Est. primary completion date | April 30, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 16 Years and older |
Eligibility |
Sperm Epigenome Arm: Cholestatic men Inclusion Criteria: - Men who have a diagnosis of a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis. - Me who are able and willing to give informed consent. Exclusion Criteria: - Men who have a history of diabetes or obesity. - Men who have gallstones, cancer or other acute cholestatic pathology. - Men who have a history of alcohol excess or drug abuse. - Men who smoke. - Men who have blood-borne viruses e.g. HIV or hepatitis. - Men unable or unwilling to give informed consent Healthy men Inclusion Criteria: - Men who have no history of cholestasis, liver disease, diabetes or obesity. - Me who are able and willing to give informed consent. Exclusion Criteria: - Men who have a history of cholestasis or liver disease. - Men who have a history of diabetes or obesity. - Men who have a history of alcohol excess or drug abuse. - Men who smoke. - Men who have blood-borne viruses e.g. HIV or hepatitis. - Men undergoing fertility treatment due to male factor. - Men unable or unwilling to give informed consent Outcomes Arm: Fathers Inclusion Criteria: - Fathers with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis. - Fathers with cholestatic liver condition whose children are between 16 years - 25 years of age. - Fathers with cholestatic liver condition who are able and willing to give informed consent. Exclusion Criteria: - Fathers with a history of diabetes or obesity at the time of conception of their child. - Fathers with a history of alcohol excess or drug-abuse at the time of conception of their child. - Fathers who smoked at the time of conception of their child. - Fathers with blood-borne viruses e.g. HIV and hepatitis at the time of conception of their child. - Fathers unable or unwilling to give informed consent. Children of cholestatic fathers Inclusion Criteria: - Adolescents / young adults (between 16 - 25 years of age) whose fathers have a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis or Primary Biliary Cholangitis. - Adolescents /young adults born from an uncomplicated singleton pregnancy. - Adolescents /young adults who are able and willing to give informed consent. Exclusion Criteria: - Adolescents / young adults who were born as a result of multi-fetal pregnancy. - Adolescents / young adults with a history of alcohol excess or drug-abuse. - Adolescents / young adults who are under 16 years of age, or over 25 years of age. - Adolescents / young adults with blood-borne viruses e.g. HIV and hepatitis. - Adolescents / young adults who are unable or unwilling to give informed consent. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Assisted Conception Unit, Guy's Hospital | London | |
United Kingdom | King's College Hospital | London |
Lead Sponsor | Collaborator |
---|---|
Guy's and St Thomas' NHS Foundation Trust | King's College Hospital NHS Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Impact of male cholestasis on DNA methylation patterns in sperm | 01/04/2018 | ||
Primary | Impact of male cholestasis on small RNA content in sperm | 01/04/2018 | ||
Primary | Impact of male cholestasis on sperm histone retention | 01/04/2018 | ||
Primary | Impact of paternal cholestasis on the BMI, hip and waist girth of their adolescent / young adult children | 01/04/2018 | ||
Primary | Impact of paternal cholestasis on the general health of their adolescent / young adult children | The prevalence of heart, lung, diabetes, thyroid, kidney or liver disease in children of fathers with cholestasis will be investigated | 01/04/2018 | |
Secondary | Impact of male cholestasis on seminal fluid composition. | 01/04/2018 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02239211 -
A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis
|
Phase 2 | |
Withdrawn |
NCT03216876 -
A Study Of Ursolic Acid For Primary Sclerosing Cholangitis
|
Phase 1 | |
Recruiting |
NCT02605213 -
Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients
|
Phase 4 | |
Recruiting |
NCT01688024 -
Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis
|
Phase 2 | |
Completed |
NCT03041662 -
Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)
|
||
Completed |
NCT05866809 -
Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis
|
Phase 2 | |
Recruiting |
NCT05618145 -
National Database on Primary Sclerosing Cholangitis (PSC)
|
||
Active, not recruiting |
NCT02446665 -
Disease Status in Primary Sclerosing Cholangitis by Elastography
|
N/A | |
Completed |
NCT02247934 -
Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)
|
N/A | |
Completed |
NCT01088607 -
Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis
|
Phase 1 | |
Terminated |
NCT01142323 -
Pilot Study of Fenofibrate for PSC
|
Phase 1/Phase 2 | |
Terminated |
NCT04060147 -
Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
|
Phase 1 | |
Recruiting |
NCT04133792 -
Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)
|
Phase 3 | |
Active, not recruiting |
NCT04595825 -
CM-101 in PSC Patients -The SPRING Study
|
Phase 2 | |
Recruiting |
NCT03183570 -
Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT
|
Early Phase 1 | |
Completed |
NCT02943460 -
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis
|
Phase 2 | |
Completed |
NCT00951327 -
Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP)
|
N/A | |
Completed |
NCT04024813 -
A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC
|
Phase 2 | |
Recruiting |
NCT05912387 -
Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
|
Early Phase 1 | |
Completed |
NCT02884557 -
NKT Role in the Regulation of the Inflammatory Bowel Disease
|
N/A |